FDA Proposes New Guidelines to Certify AI Medical Devices Rapidly

The FDA's existing regulatory framework is inadequate for the swift advancements in adaptive artificial intelligence (AI) and machine learning (ML) in medical devices, prompting proposals for new guidelines focused on lifecycle management and marketing submissions. In support of this innovation, bipartisan senators have introduced the Health Tech Investment Act, aimed at creating a Medicare reimbursement pathway for FDA-cleared AI and ML technologies. Dr. Erik Langhoff points out that the FDA is expected to certify over 1,200 AI applications by July 2025, primarily in radiology, underscoring the need for an agile certification process that maintains high safety standards. The evolving landscape presents significant implications for healthcare professionals, emphasizing the necessity for transparency and consumer assurance in the deployment of these advanced technologies.

Opens on mobihealthnews